查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594613

基于肿瘤学的体内 CRO 市场：按服务、适应症和最终用户划分 - 全球预测 2025-2030 年

Oncology Based In-Vivo CRO Market by Services (Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies), Indication (Hematological Malignancies, Rare Cancer, Solid Tumor), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，基于肿瘤的体内CRO市场估值为12.7亿美元，预计到2024年将达到14.1亿美元，复合年增长率为11.34%，到2030年将达到27亿美元。

基于肿瘤学的体内 CRO（合约委外研发机构）为临床前测试提供广泛的服务，重点是对新型癌症治疗的体内全面评估。更准确地说，这些 CRO 进行评估癌症药物的功效、安全性和药物动力学的研究，促进药物开发的关键步骤。这种需求源于对个人化医疗日益增长的需求以及对有效癌症治疗的持续追求。它具有广泛的应用，包括药物发现、转化研究和监管提交，并被製药公司、研究机构、生物技术公司和其他最终用户使用。推动该市场的主要成长要素包括全球癌症发生率上升、肿瘤学研究投资增加以及动物建模技术进步。

主要市场统计
基准年[2023] 12.7亿美元
预测年份 [2024] 14.1亿美元
预测年份 [2030] 27亿美元
复合年增长率（%） 11.34%

随着人工智慧和巨量资料分析的集成，现代商机不断涌现，以增强临床结果的预测模型并简化药物开发流程。与学术界和新兴生物技术公司合作进行创新且具有成本效益的试验设计也是一个有前途的途径。然而，这个市场面临着严格的监管要求和动物测试的道德问题等挑战，这使得测试过程变得缓慢和复杂。此外，与体外模型的竞争以及相关人员因成本限製而不愿意是主要障碍。

市场开拓可以集中于开发更具预测性和人性化的体内模型、引入数位生物标记以及提高从动物实验中收集的资料的准确性。公司应考虑投资能够提高结果可重复性并降低流失率的技术。该市场的动态本质强调对新的科学进步和监管变化的适应能力。寻求发展的公司应优先考虑建立策略伙伴关係、投资个人化测试模型并遵守不断发展的全球标准，以便在这个快速发展的领域中获得竞争优势。

市场动态：针对快速发展的基于肿瘤学的体内 CRO 市场揭示的关键市场洞察

基于肿瘤学的体内 CRO 市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 癌症发生率增加和有效药物发现的需求
    • 对优化和高效的癌症临床试验活动的需求日益增长
    • 政府鼓励个人化医疗的倡议
  • 市场限制因素
    • 资料安全和隐私问题
  • 市场机会
    • 透过资料分析和人工智慧，基于肿瘤学的体内技术取得进展
    • 扩大肿瘤学 CRO 服务以开发生物标记
  • 市场挑战
    • 癌症临床试验中监管合规性的限制

波特五力：驾驭肿瘤体内 CRO 市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解基于肿瘤学的体内 CRO 市场的外部影响

外部宏观环境因素在塑造基于肿瘤的体内 CRO 市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解基于肿瘤学的体内 CRO 市场的竞争格局

基于肿瘤学的体内 CRO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵基于肿瘤学的体内 CRO 市场供应商绩效评估

FPNV 定位矩阵是评估基于肿瘤的体内 CRO 市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为肿瘤体内 CRO 市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，基于肿瘤学的体内 CRO 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加以及有效新药发现的需求
      • 对优化和高效的肿瘤临床试验活动的需求日益增长
      • 政府鼓励个人化医疗的倡议
    • 抑制因素
      • 资料安全和隐私问题
    • 机会
      • 利用资料分析和人工智慧的基于肿瘤学的体内技术的进展
      • 扩大肿瘤学 CRO 服务以开发生物标记
    • 任务
      • 肿瘤学试验中监管合规性的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章基于肿瘤的体内 CRO 市场：按服务分类

  • 生物标誌物开发
  • 临床试验管理
  • 药物动力学研究
  • 临床前研究

第七章基于肿瘤的体内 CRO 市场（按适应症）

  • 造血系统恶性
  • 罕见癌症
  • 固态肿瘤

第八章基于肿瘤学的体内 CRO 市场：按最终用户分类

  • 学术研究所
  • 生技公司
  • 製药公司

第九章美洲基于肿瘤的体内 CRO 市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区以肿瘤为基础的体内 CRO 市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲基于肿瘤的体内 CRO 市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Altogen Labs
  • Cellvax, SAS
  • Charles River Laboratory
  • Crown Bioscience
  • Cyagen Biosciences
  • Evotec SE
  • Explicyte by Immusmol SAS Company
  • Icon PLC
  • Imavita
  • IVRS AB
  • Laboratory Corporation of America Holdings
  • Melior Discovery
  • Noble Life Sciences
  • Pharmaron
  • Pharmatest Services
  • Reaction Biology by Copeba
  • Redoxis AB
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • XenTech
Product Code: MRR-FF012EDC38C0

The Oncology Based In-Vivo CRO Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.41 billion in 2024, and is projected to grow at a CAGR of 11.34%, to USD 2.70 billion by 2030.

The scope of oncology-based in-vivo CROs (Contract Research Organizations) involves providing a wide range of services for preclinical studies, focusing on the comprehensive assessment of novel cancer therapies in living organisms. Precisely, these CROs conduct studies that evaluate the efficacy, safety, and pharmacokinetics of oncology drugs, facilitating a critical step in drug development. Their necessity stems from the increasing demand for personalized medicine and the relentless pursuit of effective cancer treatments. Applications are versatile, including drug discovery, translational research, and regulatory submissions, serving end-uses in pharmaceutical companies, research institutions, and biotech firms. Key growth factors driving this market include the rising incidence of cancer worldwide, growing investments in oncology research, and technological advancements in animal modeling.

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.41 billion
Forecast Year [2030] USD 2.70 billion
CAGR (%) 11.34%

Latest opportunities are emerging with the integration of artificial intelligence and big data analytics, which enhance the predictive modeling of clinical outcomes and streamline drug development processes. Leveraging collaborations with academia and emerging biotech for innovative, cost-effective study designs is also a promising avenue. However, the market faces challenges such as stringent regulatory requirements and ethical concerns related to animal testing, which can delay and complicate study processes. Additionally, competition from in-vitro models and reluctance from stakeholders due to cost constraints are substantial barriers.

Market innovations could focus on developing more predictive and humane in-vivo models, incorporating digital biomarkers, and enhancing the precision of data gathered from animal studies. Companies should consider investing in technologies that improve the reproducibility of results and reduce attrition rates. The nature of this market is dynamic, with a strong emphasis on the adaptability to new scientific advancements and regulatory changes. Businesses aiming for growth should prioritize forming strategic partnerships, investing in personalized study models, and ensuring compliance with evolving global standards to secure a competitive advantage in this rapidly evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of cancer and need for effective drug discovery
    • Rising need for optimized and efficient oncology clinical trial activities
    • Government initiatives encouraging personalized medicine
  • Market Restraints
    • Concerns associated with data security and privacy
  • Market Opportunities
    • Advancements in oncology-based in-vivo technologies with data analytics and AI
    • Expansion of oncology CRO services for biomarker development
  • Market Challenges
    • Limitations of regulatory compliance of oncology trials

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Based In-Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Based In-Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Based In-Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Based In-Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Based In-Vivo CRO Market

A detailed market share analysis in the Oncology Based In-Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Based In-Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Based In-Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Based In-Vivo CRO Market

A strategic analysis of the Oncology Based In-Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.

Market Segmentation & Coverage

This research report categorizes the Oncology Based In-Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Services, market is studied across Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies, and Preclinical Studies.
  • Based on Indication, market is studied across Hematological Malignancies, Rare Cancer, and Solid Tumor.
  • Based on End-User, market is studied across Academic & Research Institutes, Biotechnology Companies, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
      • 5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
      • 5.1.1.3. Government initiatives encouraging personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with data security and privacy
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
      • 5.1.3.2. Expansion of oncology CRO services for biomarker development
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of regulatory compliance of oncology trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Based In-Vivo CRO Market, by Services

  • 6.1. Introduction
  • 6.2. Biomarker Development
  • 6.3. Clinical Trial Management
  • 6.4. Pharmacokinetics Studies
  • 6.5. Preclinical Studies

7. Oncology Based In-Vivo CRO Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematological Malignancies
  • 7.3. Rare Cancer
  • 7.4. Solid Tumor

8. Oncology Based In-Vivo CRO Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Biotechnology Companies
  • 8.4. Pharmaceutical Companies

9. Americas Oncology Based In-Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncology Based In-Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Altogen Labs
  • 2. Cellvax, SAS
  • 3. Charles River Laboratory
  • 4. Crown Bioscience
  • 5. Cyagen Biosciences
  • 6. Evotec SE
  • 7. Explicyte by Immusmol SAS Company
  • 8. Icon PLC
  • 9. Imavita
  • 10. IVRS AB
  • 11. Laboratory Corporation of America Holdings
  • 12. Melior Discovery
  • 13. Noble Life Sciences
  • 14. Pharmaron
  • 15. Pharmatest Services
  • 16. Reaction Biology by Copeba
  • 17. Redoxis AB
  • 18. Taconic Biosciences, Inc.
  • 19. The Jackson Laboratory
  • 20. XenTech

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY BASED IN-VIVO CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACOKINETICS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RARE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023